Dare to lead : public health and company wealth : Oxfam briefing paper on GlaxoSmithKline.
Material type:
TextPublication details: Oxford : OXFAM, 2001. Description: 36 pSubject(s): Drug industry | Drug costs | PatentsNLM classification: QV 736 2001DA
| Item type | Current library | Call number | Copy number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
Books
|
WHO HQ BORROWABLE-COLL-STACKS | QV 736 2001DA (Browse shelf(Opens below)) | 1 | Available | 00066280 |
Browsing WHO HQ shelves, Shelving location: BORROWABLE-COLL-STACKS Close shelf browser (Hides shelf browser)
| No cover image available | No cover image available | No cover image available | No cover image available | |||||
| QV 736 2000LE-1 Les politiques de forfaits de remboursement des médicaments en Allemagne et au Pays-Bas / | QV 736 2000MU World Trade Organisation agreements : | QV 736 2001CO Consolidation and competition in the pharmaceutical industry / | QV 736 2001DA Dare to lead : | QV 736 2001FA Fatal side effects : | QV 736 2001IN Introduction to applied pharmacoeconomics | QV 736 2001PA Patent injustice : |
This report was produced by the Policy Department of Oxfam (Great Britain) as part of the "Cut the cost of Medicines" campaign.
4
There are no comments on this title.